Helbert Rondon-Berrios University of Pittsburgh School of MedicineUnited States

HelbertRondon-Berrios
Dr. Rondon-Berrios is a Professor of Medicine in the Renal-Electrolyte Division at the University of Pittsburgh School of Medicine where he also serve as the Program Director of the Nephrology Fellowship Training Program. Dr. Rondon-Berrios obtained his MD degree at Universidad Nacional Mayor de San Marcos in Lima, Peru. He then completed Internal Medicine Residency training at University of Texas Medical Branch in Galveston, Texas followed by Nephrology Fellowship at University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania where he also received a Master of Science degree in medical education. Dr. Rondon-Berrios has authored several publications in the area of hyponatremia. He had received NIH funding to study the role of oral urea in the management of chronic hyponatremia. His current research focus on the efficacy and safety profile of desmopressin to prevent rapid correction of hyponatremia, and the neurological outcomes of profound hyponatremia (plasma sodium < 110 mmol/L).
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
Precise Phenotyping and Treatment
ChairpersonHeather Reich University of Toronto, University Health NetworkCanada
ChairpersonSebastián Jaurretche sebastianjaurretche@hotmail.comSanatorio Parque SAArgentina
  • Deciphering the IGAN Cell Atlas
    SpeakerJulio Saez-Rodriguez julio.saez@uni-heidelberg.deHeidelberg UniversityGermany
  • Complement-mediated Kidney Diseases in the Era of Complement Inhibitors
    SpeakerMarina Vivarelli marina.vivarelli@opbg.netLaboratory of Nephrology, Bambino Gesù Children's HospitalItaly
  • CART-T
    SpeakerJonathan Hogan jonathan.hogan@cabalettabio.comCabaletta Bio
  • New Targets to Reduce the Burden of Rare Kidney Diseases
    SpeakerLaura Mariani lmariani@umich.eduUniversity of MichiganUnited States
  • Q and A
Hall C4
11 a.m.
12 p.m.
Plenary Session 2: CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? (Obiageli Eunice Nnodu, Nigeria)
ChairpersonAgnes Fogo United States
ChairpersonGuillermo Rosa Diez guillermo.rosadiez@hospitalitaliano.org.arHospital Italiano de Buenos Aires; Argentinean Society of Nephrology; Latinoamerican Society of Nephrology and Hypertension; International Society of NephrologyArgentina
  • My Story
    SpeakerVictoria Gray vwright_03@yahoo.comUnited States
  • CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? Hugh de Wardener Lecture
    SpeakerObiageli Eunice Nnodu oennodu@gmail.comUniversity of AbujaNigeria
Hall A
12:15 p.m.
1:15 p.m.
Hot Debate: Should a Low Protein Diet (+/- Ketoanalogue Supplementation) Be Part of Advanced CKD Management?
ChairpersonCarla Avesani carla.avesani@ki.seKarolinska InstituteSweden
ChairpersonSahir Kalim skalim@mgh.harvard.eduHarvard Medical School/ Massachusetts General Hospital United States
  • Hot Debate: Should Low Protein Diet (+/- Ketoanalogue Supplementation) Be a Part of Advanced CKD Management? - PROS
    SpeakerConnie Rhee crhee@mednet.ucla.eduUCLAUnited States
  • Hot Debate: Should Low Protein Diet (+/- Ketoanalogue Supplementation) Be a Part of Advanced CKD Management? - CONS
    SpeakerSwapnil Hiremath University of OttawaCanada
Hall A
3 p.m.
4 p.m.
A Balancing Act: Your Kidneys and Electrolytes
ChairpersonAngela Yee-Moon Wang Hong Kong/SingaporeSingapore
ChairpersonThiago De Azevedo Reis thiagoreisnefro@gmail.comHospital Sírio-Libanês, São Paulo, Brazil & Fenix Brazil
  • Is Magnesium a Missing Puzzle for Vascular Calcification in CKD?
    SpeakerSola Aoun Bahous sola.bahous@gmail.comLebanese American University School of MedicineLebanon
  • Should Potassium Be Restricted or Not in CKD?
    SpeakerRoberto Pecoits Filho Arbor Research Collaborative for HealthUnited States
  • Metabolic Acidosis in CKD: When to Treat? What to Target?
    SpeakerMitchell Rosner Univeristy of Virginia HealthUnited States
  • Q and A
Hall A
Cardiorenal Syndrome: Updates in the Pathophysiology and State-of-the-Art Treatment
ChairpersonFelipe Inserra felipe.inserra@gmail.comArgentina
ChairpersonYelena Drexler yrd6@miami.eduUniversity of Miami Miller School of MedicineUnited States
  • New Insights into the Mechanisms of Kidney Injury in the CRS
    SpeakerWendy Mccallum wmccallum@tuftsmedicalcenter.orgUnited States
  • Novel Pharmacological Treatments of the CRS
    SpeakerMark Sarnak msarnak@tuftsmedicalcenter.orgTufts Medical CenterUnited States
  • Device-related Treatment for CRS
    SpeakerClaudio Ronco cronco@goldnet.itInternational Renal Research Institute of VicenzaItaly
  • Q and A
Hall D
4:30 p.m.
5:30 p.m.
Building Competency in Nephrology Education
ChairpersonAugusto Cesar Soares dos Santos Junior Hospital das Clinicas, UFMG; Fac Ciências MedicasBrazil
ChairpersonLi-Li Hsiao lhsiao@bwh.harvard.eduBrigham and Women\'s Hospital, Harvard Medical SchoolUnited States
  • Curriculum Design to Developing Competency in Nephrology Practice
    SpeakerRene Scalet Dos Santos Neto renesantosneto@gmail.comFaculdades Pequeno Principe (FPP) - BrazilBrazil
  • Developing Clinical Reasoning
    SpeakerKaren Warburton KMW2G@uvahealth.orgUniversity of Virginia Health SystemUnited States
  • Assessment of Nephrology Trainees to Ensure Competence
    SpeakerSola Aoun Bahous sola.bahous@gmail.comLebanese American University School of MedicineLebanon
  • Q and A
Hall C2
Salt Substitutes and HTN/CVD
ChairpersonConnie Rhee crhee@mednet.ucla.eduUCLAUnited States
ChairpersonGerardo Gamba gamba@biomedicas.unam.mxUniversidad Nacional Autónoma de MéxicoMexico
  • Potassium-based Salt Substitutes and CVD
    SpeakerHoorn Ewout e.j.hoorn@erasmusmc.nlErasmus Medical Center, Rotterdam, The NetherlandsNetherlands
  • Strategies for Scaling the Use of Potassium-enriched Salt
    SpeakerBruce Neal lclifford@georgeinstitute.org.auThe George Institute, UNSW, Imperial CollegeAustralia
  • Use of Salt Meters to Reduce Salt Intake
    SpeakerSurasak Kantachuvesiri Nephrology Division, Faculty of Medicine, RamathibThailand
  • Q and A
Hall E

Day 2 - Monday April 15, 2024

Time Session
3 p.m.
4 p.m.
Treatment Goals for Severe Hyponatremia: A Debate on Current Guidelines Program
ChairpersonMitchell Rosner Univeristy of Virginia HealthUnited States
  • Overview of Hyponatremia
    SpeakerAngela Yee-Moon Wang Hong Kong/SingaporeSingapore
  • Pro: Current Guidelines are Appropriate
    SpeakerHelbert Rondon-Berrios rondonberriosh@upmc.eduUniversity of Pittsburgh School of MedicineUnited States
  • Con: Current Guidelines are Too Conservative
    SpeakerCarlos Ayus carlosayus@yahoo.comUniversity of California IrvineUnited States
  • Discussion
Hall C3
3:45 p.m.
4:45 p.m.
Young Nephrologists Quiz-a-Thon
Spotlight ChairpersonMarina Wainstein Academia Nacional de Medicina de Buenos AiresArgentina
Spotlight Stage 1 (exhibition hall)

Day 3 - Tuesday April 16, 2024

Time Session
9 a.m.
10 a.m.
Type 2 Diabetes in Kidney Disease: Recent Updates and Best Practices for Detection and Treatment
ChairpersonDebasish Banerjee St George's University Hospital NHS Foundation TrUnited Kingdom
ChairpersonMeg Jardine NHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
  • Setting the Scene
    SpeakerMeg Jardine NHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
  • DM and CKD: Which Treatment Should I Use for Different Populations?
    SpeakerKatherine Tuttle University of Washington School of Medicine, Division of NephrologyUnited States
  • How to Design Studies on Answering Unanswered Questions
    SpeakerVlado Perkovic University of New South Wales, Sydney, AustraliaAustralia
  • The Effect of SGLT2 Inhibitors in Patients with Chronic Kidney Disease, With or Without Type 2 Diabetes
    SpeakerDavid Wheeler University College LondonUnited Kingdom
  • Q and A
Hall C4
Hi Aldo, What's New? Advances in Aldosterone in Health and Disease
ChairpersonCarlos Schreck carlos.schreck@gmail.comHospital Italiano de Buenos Aires- NephrologyArgentina
ChairpersonKelly Haughton kidneydoctorpanama@gmail.comSLANH, PanamaPanama
  • Why Are Fewer Than I% Of Hypertensive Patients Ever Screened For Primary Aldosteronism?
    SpeakerJohn Funder John.Funder@hudson.org.auThe Hudson Institute of Medical Research Clayton 3168 Victoria Australia; Monash University, Clayton 3600 Victoria AustraliaAustralia
  • Aldosterone and Disease
    SpeakerJordana Cohen jco@pennmedicine.upenn.eduUniversity of PennsylvaniaUnited States
  • New Trials Using Aldosterone Synthese Blockade
    SpeakerMichel Azizi michel.azizi@aphp.frUniversité Paris Cité, Hypertension department, HôFrance
  • Targeting MR for Heart and Kidney Protection
    SpeakerHiddo Lambers Heerspink H.J.Lambers.Heerspink@umcg.nlNetherlands
  • Q and A
Hall E
9 a.m.
10:30 a.m.
Clinical Management of Glomerulonephritis (GN)
ChairpersonJuan Manuel Mejia Vilet jmmejia@hotmail.comInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico
ChairpersonValeria Alberton vgalberton@gmail.comHospital Fernandez/ Hospital El CruceArgentina
  • Updates on IgAN Management
    SpeakerHernán Trimarchi HOSPITAL BRITÁNICO DE BUENOS AIRESArgentina
  • Membranous GN Classification and Management
    SpeakerPierre Ronco Hôpital TenonFrance
  • MPGN Updates
    SpeakerSanjeev Sethi Mayo ClinicUnited States
  • Managing Vasculitis
    SpeakerRoberta Fenoglio roberta.fenoglio@unito.itOspedale San Giovanni BoscoItaly
  • Q and A
Hall A
11 a.m.
12:15 p.m.
Plenary Session 4: Insights into SGLT2 Inhibitors: A Story of Discovery (Ele Ferrannini, Italy)
ChairpersonAlessia Fornoni University of Miami United States
ChairpersonLiz Lightstone Imperial College LondonUnited Kingdom
ChairpersonMasaomi Nangaku Japan
  • Acceptance Speech: Bywaters Award
    SpeakerMotoko Yanagita Kyoto UniversityJapan
  • Insights into SGLT2 Inhibitors: A Story of Discovery. Donald Seldin Lecture
    SpeakerEle Ferrannini eleferrannini@gmail.comUniversity of PisaItaly
  • ELP2 Graduation
    SpeakerMasaomi Nangaku Japan
Hall A
12:30 p.m.
1:30 p.m.
Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120?
ChairpersonMarcelo Orías marcelo.orias@gmail.comArgentina
ChairpersonMark Sarnak msarnak@tuftsmedicalcenter.orgTufts Medical CenterUnited States
  • Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120? - PROS
    SpeakerTara Chang tichang@stanford.eduStanford UniversityUnited States
  • Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120? - CONS
    SpeakerJordana Cohen jco@pennmedicine.upenn.eduUniversity of PennsylvaniaUnited States
Hall A

Pre-Congress - Saturday April 13, 2024

Time Session
4:30 p.m.
6 p.m.
WCN'24 Opening Ceremony and Plenary Session 1: The Origin of the Universe (Daniel de Florian, Argentina)
  • ISN President's Address
    SpeakerMasaomi Nangaku Japan
  • Tribute to Stewart Cameron
  • Welcome by WHO Director of Non-Communicable Diseases Dr Bente Mikkelsen
  • Welcome by Dr. Marina Papaginovic, SAN President; Dr. Guillermo Rosa Diez, WCN Local Organising Group Chair; and Dr. Jorge Rico, SLANH President and WCN Local Organizing Group co-Chair
    SpeakerGuillermo Rosa Diez guillermo.rosadiez@hospitalitaliano.org.arHospital Italiano de Buenos Aires; Argentinean Society of Nephrology; Latinoamerican Society of Nephrology and Hypertension; International Society of NephrologyArgentina
    SpeakerJorge Rico jorgericof@yahoo.comColombia
    SpeakerMaria Papaginovic Leiva drapapaginovicleiva@gmail.comArgentina
  • Welcome by Minister of Health for Buenos Aries Dr Fern
  • Welcome by SPWG Chair Alessia Fornoni
    SpeakerAlessia Fornoni University of Miami United States
  • The Origin of the Universe
    SpeakerDaniel De Florian deflo@unsam.edu.arUniversidad Nacional de San MartinArgentina
  • Acceptance Speech: Hamburger Award
    SpeakerAdeera Levin University of British Columbia and Providence Health CareCanada
Hall A